Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

NCT07692048 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT07692048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07692048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Lead sponsor
Sichuan University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2028
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc